OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

globenewswire

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors – NEWSnet – News… as it used to be

More Press Releases

June 24, 2026

Global Ship Lease Announces Additional Newbuilding Orders

June 24, 2026

Prospect Floating Rate and Alternative Income Fund Announces a 14.96% Annualized Total Cash Common Shareholder Distribution Rate on Net Asset Value for June 2026

June 24, 2026

Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia

June 24, 2026

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

Global Ship Lease Announces Additional Newbuilding Orders

Prospect Floating Rate and Alternative Income Fund Announces a 14.96% Annualized Total Cash Common Shareholder Distribution Rate on Net Asset Value for June 2026

Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia

ASUS ROG Strix SCAR 18 Now Available with 320W Total System Power and New ROG Nebula Extreme Low Motion Blur (ELMB) Displays